The DOI matches its Crossref record.
Adenosine and Prostaglandin E2 Cooperate in the Suppression of Immune Responses Mediated by Adaptive Regulatory T Cells
Open accessAbstract
Adaptive regulatory T cells (Tr1) are induced in the periphery upon encountering cognate antigens. In cancer, their frequency is increased; however, Tr1-mediated suppression mechanisms are not yet defined. Here, we evaluate the simultaneous involvement of ectonucleotidases (CD39/CD73) and cyclooxygenase 2 (COX-2) in Tr1-mediated suppression. Human Tr1 cells were generated from peripheral blood mononuclear cell-derived, sorted CD4(+)CD25(-) T cells and incubated with autologous immature dendritic cells, irradiated COX-2(+) or COX-2(-) tumor cells, and IL-2, IL-10, and IL-15 (each at 10-15 IU/ml) for 10 days as described (Bergmann, C., Strauss, L., Zeidler, R., Lang, S., and Whiteside, T. L. (2007) Cancer Immunol. Immunother. 56, 1429-1442). Tr1 were phenotyped by multicolor flow cytometry, and suppression of proliferating responder cells was assessed in carboxyfluorescein diacetate succinimidyl ester-based assays. ATP hydrolysis was measured using a luciferase detection assay, and levels of adenosine or prostaglandin E(2) (PGE(2)) in cell supernatants were analyzed by mass spectrometry or ELISA, respectively. Intracellular cAMP levels were measured by enzyme immunoassay. The COX-2(+) tumor induced a greater number of Tr1 than COX-2(-) tumor (p < 0.05). Tr1 induced by COX-2(+) tumor were more suppressive, hydrolyzed more exogenous ATP (p < 0.05), and produced higher levels of adenosine and PGE(2) (p < 0.05) than Tr1 induced by COX-2(-) tumor. Inhibitors of ectonucleotidase activity, A(2A) and EP(2) receptor antagonists, or an inhibitor of the PKA type I decreased Tr1-mediated suppression (p < 0.05), whereas rolipram, a PDE(4) inhibitor, increased the intracellular cAMP level in responder cells and their susceptibility to Tr1-mediated suppression. Tr1 present in tumors or the peripheral blood of head and neck squamous cell carcinoma patients co-expressed COX-2, CD39, and CD73. A concomitant inhibition of PGE(2) and adenosine via the common intracellular cAMP pathway might be a novel approach for improving results of immune therapies for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Multifaceted roles of PGE2 in inflammation and cancer
Nakanishi, M., & Rosenberg, D. W. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0342-8 · Cited by 591
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Whiteside, T. L. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120265 · Cited by 388
Self-citationDesreumaux, P., Foussat, A., Allez, M., Beaugerie, L., Hébuterne, X., Bouhnik, Y., Nachury, M., Brun, V., Bastian, H., Belmonte, N., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.116 · Cited by 384
Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M., & Gagliani, N. (2018) · Immunity · doi:10.1016/j.immuni.2018.12.001 · Cited by 355
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
Ohta, A., & Sitkovsky, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00304 · Cited by 320
What are regulatory T cells (Treg) regulating in cancer and why?
Whiteside, T. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.004 · Cited by 291
Self-citationSchuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Self-citationAdenosine production by human B cells and B cell–mediated suppression of activated T cells
Saze, Z., Schuler, P. J., Hong, C.-S., Cheng, D., Jackson, E. K., & Whiteside, T. L. (2013) · Blood · doi:10.1182/blood-2013-02-482406 · Cited by 269
Self-citationThe Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells
Okeke, E. B., & Uzonna, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00680 · Cited by 264
Role of MSC in the Tumor Microenvironment
Hass, R. (2020) · Cancers · doi:10.3390/cancers12082107 · Cited by 116
“The release of the macrophage inflammatory proteins MIP-1α/CCL3 and MIP-2α/CXCL2 together with PGE2 and kynurenine by MSC contributes to the conversion of inflammatory M1 macrophages to alternatively activated, immunosuppressive M2 macrophages [79].”
BackgroundInfluential
Metadata
- Authors
- Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Jackson, E. K., Johnson, J. T., Gorelik, E., Lang, S., & Whiteside, T. L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 285
- Issue
- 36
- Pages
- 27571-27580
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2081551852
- Cited by
- 162
- References
- 0
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.